MRD-specific HR for relapse after chemotherapy and SCT
| Cutoff . | Risk group . | HR . | 95% CI . | P . | CVPL . | Median time to relapse (days) . | 95% CI time to relapse . |
|---|---|---|---|---|---|---|---|
| Cox models of NPM1/ABL as time-dependent covariate after chemotherapy and completion of treatment | |||||||
| NPM1/ABL 1% | Not detectable | 1 | — | — | |||
| Detectable and 1% | 3.41 | 1.15-10.06 | .03 | ||||
| >1% | 12.89 | 4.22-39.40 | <.001 | ||||
| >1% at time of CR | 1 | — | — | ||||
| 1% at time of CR | 0.86 | 0.18-4.12 | .85 | ||||
| NPM1/ABL 1% | Not detectable | 1 | — | — | |||
| Detectable and 1% | 4.09 | 1.19-14.07 | .03 | ||||
| >1% | 16.21 | 4.56-57.63 | <.001 | ||||
| >1% at time of CR | 1 | — | — | ||||
| 1% at time of CR | 1.32 | 0.52-3.32 | .56 | ||||
| NPM1/ABL 1% | Not detectable | 1 | — | — | — | 1725 | — |
| 1% | 3.41 | 1.15-10:05 | .03 | −123.38 | 372 | 208-536 | |
| >1% | 13.24 | 4.50-38.98 | <.001 | 121 | 70-172 | ||
| NPM1/ABL 1% | Not detectable | 1 | — | — | |||
| Detectable and 1% | 3.90 | 1.30-11.69 | .015 | FLT3 wt: 372 | 231-513 | ||
| FLT3-ITD1: 875 | 0-1800 | ||||||
| >1% | 13.04 | 4.45-38.25 | <.001 | FLT3 wt: 261 | — | ||
| FLT3-ITD1: 85 | — | ||||||
| FLT3-ITDwt | 1 | — | — | ||||
| FLT3-ITD+ | 2.59 | 1.13-5.96 | .025 | ||||
| Cox models of NPM1/ABL as time-dependent covariate after SCT | |||||||
| NPM1/ABL 10%* | Not detectable | 1 | — | — | — | — | |
| ≤10% | 1.84 | 0.19-17.76 | .60 | — | — | ||
| >10% | 61.41 | 10.35-364.20 | <.001 | −0.6 | 68 | — | |
| Cutoff . | Risk group . | HR . | 95% CI . | P . | CVPL . | Median time to relapse (days) . | 95% CI time to relapse . |
|---|---|---|---|---|---|---|---|
| Cox models of NPM1/ABL as time-dependent covariate after chemotherapy and completion of treatment | |||||||
| NPM1/ABL 1% | Not detectable | 1 | — | — | |||
| Detectable and 1% | 3.41 | 1.15-10.06 | .03 | ||||
| >1% | 12.89 | 4.22-39.40 | <.001 | ||||
| >1% at time of CR | 1 | — | — | ||||
| 1% at time of CR | 0.86 | 0.18-4.12 | .85 | ||||
| NPM1/ABL 1% | Not detectable | 1 | — | — | |||
| Detectable and 1% | 4.09 | 1.19-14.07 | .03 | ||||
| >1% | 16.21 | 4.56-57.63 | <.001 | ||||
| >1% at time of CR | 1 | — | — | ||||
| 1% at time of CR | 1.32 | 0.52-3.32 | .56 | ||||
| NPM1/ABL 1% | Not detectable | 1 | — | — | — | 1725 | — |
| 1% | 3.41 | 1.15-10:05 | .03 | −123.38 | 372 | 208-536 | |
| >1% | 13.24 | 4.50-38.98 | <.001 | 121 | 70-172 | ||
| NPM1/ABL 1% | Not detectable | 1 | — | — | |||
| Detectable and 1% | 3.90 | 1.30-11.69 | .015 | FLT3 wt: 372 | 231-513 | ||
| FLT3-ITD1: 875 | 0-1800 | ||||||
| >1% | 13.04 | 4.45-38.25 | <.001 | FLT3 wt: 261 | — | ||
| FLT3-ITD1: 85 | — | ||||||
| FLT3-ITDwt | 1 | — | — | ||||
| FLT3-ITD+ | 2.59 | 1.13-5.96 | .025 | ||||
| Cox models of NPM1/ABL as time-dependent covariate after SCT | |||||||
| NPM1/ABL 10%* | Not detectable | 1 | — | — | — | — | |
| ≤10% | 1.84 | 0.19-17.76 | .60 | — | — | ||
| >10% | 61.41 | 10.35-364.20 | <.001 | −0.6 | 68 | — | |
No estimate for MRD levels between the limit of detection and the cutoff is provided due to sparse observations. After SCT, the results for 5% and 10% NPM1/ABL1 are identical. For further analysis, we decided to choose the 10% level, because of 1-log increase in comparison with the identified cutoff after chemotherapy. HR, hazard ratio; CI, confidence interval; CR, complete remission; wt, wild type; ITD+, internal tandem duplication.